belatacept
Sign in to saveAlso known as LEA029, BMS-224818, Nujolix, LEA29Y, CD152 antigen, CTLA4-Ig, LEA 29Y, BMS224818
Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant
In the Vinony graph
Within Vinony's link graph, belatacept is referenced by 173 other articles, and connects out to immunosuppressive drug, lumiliximab and medication.
It sits within the topics Chemicals that do not have a ChemSpider ID assigned, Drugboxes which contain changes to verified fields and Drug has EMA link.
Its subject is documented across 14 Wikipedia language editions.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2011
- Admin. routes
- parenteral
- Indications
- immune system disease, Proteinuria, rheumatoid arthritis, acute graft vs. host disease
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 4 more facts
- World Health Organisation international non-proprietary name
- belatacept
- defined daily dose
- 12.5
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- External links
Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.
Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011.
Excerpted from Wikipedia’s “belatacept” article, available under the CC BY-SA 4.0 licence.